| Title |
Non-24-hour sleep–wake syndrome improved by low-dose valproic acid: a case report
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, December 2016
|
| DOI | 10.2147/ndt.s115648 |
| Pubmed ID | |
| Authors |
Masatake Kurita, Takahiro Moriya, Satoshi Nishino, Eishin Hirata, Noriyasu Hirasawa, Yoshiro Okubo, Tadahiro Sato |
| Abstract |
A woman was diagnosed with non-24-hour sleep-wake syndrome and depressive symptoms. Her depressive symptoms did not respond to standard doses of several antidepressants or mood stabilizers. Furthermore, her sleep-wake cycle remained non-entrained despite treatment with a melatonin-related drug, vitamin B12, and phototherapy. Ultimately, her sleep-wake rhythm was restored to a 24-hour pattern with a low dose of valproic acid, and her depressive symptoms tended to improve as a result of synchronization without antidepressants. Low-dose valproic acid appears to be one of the effective means of entraining circadian rhythms in patients with non-24-hour sleep-wake syndrome, which in turn likely improves associated depressive symptoms. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Japan | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 2 | 11% |
| Researcher | 2 | 11% |
| Student > Postgraduate | 2 | 11% |
| Student > Bachelor | 1 | 6% |
| Student > Master | 1 | 6% |
| Other | 3 | 17% |
| Unknown | 7 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 28% |
| Neuroscience | 3 | 17% |
| Nursing and Health Professions | 1 | 6% |
| Psychology | 1 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 7 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2024.
All research outputs
#8,510,599
of 25,459,177 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,148
of 3,133 outputs
Outputs of similar age
#141,336
of 416,977 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#18
of 54 outputs
Altmetric has tracked 25,459,177 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 3,133 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,977 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.